A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

BACKGROUND: Mutations of the DNA repair proteins BRCA1/2 are synthetically lethal with the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), which when inhibited, leads to cell death due to the absence of compensatory DNA repair mechanism. The potency of PARP inhibitors has now been clinically p...

Descripción completa

Detalles Bibliográficos
Autores principales: Senhaji Mouhri, Zhor, Goodfellow, Elliot, Jean-Claude, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553999/
https://www.ncbi.nlm.nih.gov/pubmed/28800752
http://dx.doi.org/10.1186/s12885-017-3504-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553999/
https://www.ncbi.nlm.nih.gov/pubmed/28800752
http://dx.doi.org/10.1186/s12885-017-3504-1

Ejemplares similares